
Roger E G Schutgens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3718334/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B. Blood, 2018, 131, 1022-1031.	0.6	236
2	Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia, 2011, 17, 849-853.	1.0	212
3	How I treat age-related morbidities in elderly persons with hemophilia. Blood, 2009, 114, 5256-5263.	0.6	175
4	COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year. Lancet Haematology,the, 2021, 8, e524-e533.	2.2	174
5	Combination of a Normal D-Dimer Concentration and a Non-High Pretest Clinical Probability Score Is a Safe Strategy to Exclude Deep Venous Thrombosis. Circulation, 2003, 107, 593-597.	1.6	167
6	Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, The, 2014, 348, g1340-g1340.	3.0	154
7	Effect of Repetitive Intra-Arterial Infusion of Bone Marrow Mononuclear Cells in Patients With No-Option Limb Ischemia. Circulation, 2015, 131, 851-860.	1.6	145
8	Out of hospital treatment of acute pulmonary embolism in patients with a low NTâ€proBNP level. Journal of Thrombosis and Haemostasis, 2010, 8, 1235-1241.	1.9	123
9	Cardiovascular disease in patients with hemophilia. Journal of Thrombosis and Haemostasis, 2009, 7, 247-254.	1.9	105
10	Coâ€morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia, 2009, 15, 853-863.	1.0	94
11	Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica, 2012, 97, 1507-1513.	1.7	93
12	Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacological Research, 2017, 115, 192-199.	3.1	93
13	Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. Journal of Thrombosis and Haemostasis, 2009, 7, 2035-2041.	1.9	84
14	Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia, 2009, 15, 952-958.	1.0	70
15	Increased prevalence of hypertension in haemophilia patients. Thrombosis and Haemostasis, 2012, 108, 750-755.	1.8	66
16	IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and is a potential target for therapy. Blood, 2015, 126, 2239-2246.	0.6	66
17	FactorÂVIII deficiency does not protect against atherosclerosis. Journal of Thrombosis and Haemostasis, 2012, 10, 30-37.	1.9	64
18	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis, 2013, 109, 16-23.	1.8	62

#	Article	IF	CITATIONS
19	Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials, 2015, 16, 393.	0.7	59
20	Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine inÂvivo study. Osteoarthritis and Cartilage, 2015, 23, 63-69.	0.6	54
21	Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. Haemophilia, 2013, 19, 833-840.	1.0	52
22	Review of immune tolerance induction in hemophilia A. Blood Reviews, 2018, 32, 326-338.	2.8	51
23	Coronary Artery Calcification in Hemophilia A. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 799-804.	1.1	50
24	Reduced efficacy of clinical probability score and d-dimer assay in elderly subjects suspected of having deep vein thrombosis. British Journal of Haematology, 2005, 129, 653-657.	1.2	48
25	Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thrombosis Research, 2012, 130, 157-162.	0.8	47
26	Identification and expression of iron regulators in human synovium: evidence for upregulation in haemophilic arthropathy compared to rheumatoid arthritis, osteoarthritis, and healthy controls. Haemophilia, 2013, 19, e218-27.	1.0	47
27	Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. American Journal of Hematology, 2019, 94, 575-584.	2.0	47
28	The detrimental effects of iron on the joint: a comparison between haemochromatosis and haemophilia. Journal of Clinical Pathology, 2015, 68, 592-600.	1.0	46
29	Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology, The, 2021, 20, 907-916.	4.9	44
30	The usefulness of five d-dimer assays in the exclusion of deep venous thrombosis. Journal of Thrombosis and Haemostasis, 2003, 1, 976-981.	1.9	43
31	Von Willebrand factor deficiency and atherosclerosis. Blood Reviews, 2012, 26, 189-196.	2.8	43
32	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a crossâ€sectional study. Haemophilia, 2015, 21, e185-92.	1.0	43
33	Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia, 2012, 18, 263-267.	1.0	42
34	Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. Blood, 2019, 134, 2059-2059.	0.6	42
35	The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica, 2005, 90, 214-9.	1.7	41
36	Differentiating between signs of intraâ€articular joint bleeding and chronic arthropathy in haemophilia: a narrative review of the literature. Haemophilia, 2015, 21, 289-296.	1.0	39

#	Article	IF	CITATIONS
37	New concepts for anticoagulant therapy in persons with hemophilia. Blood, 2016, 128, 2471-2474.	0.6	39
38	Validation of flow cytometric analysis of platelet function in patients with a suspected platelet function defect. Journal of Thrombosis and Haemostasis, 2018, 16, 689-698.	1.9	38
39	Differential effects of bleeds on the development of arthropathy – basic and applied issues. Haemophilia, 2017, 23, 521-527.	1.0	37
40	Atrial fibrillation in patients with haemophilia: a crossâ€ s ectional evaluation in Europe. Haemophilia, 2014, 20, 682-686.	1.0	36
41	Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thrombosis and Haemostasis, 2016, 115, 931-938.	1.8	36
42	Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis, 2017, 15, 1728-1736.	1.9	34
43	An ageâ€∎dapted approach for the use of Dâ€dimers in the exclusion of deep venous thrombosis. American Journal of Hematology, 2009, 84, 488-491.	2.0	33
44	Comparing findings of routine Haemophilia Joint Health Score and Haemophlia Early Arthropathy Detection with UltraSound assessments in adults with haemophilia. Haemophilia, 2017, 23, e141-e143.	1.0	33
45	Risk stratification of patients with pulmonary embolism based on pulse rate and D-dimer concentration. Thrombosis and Haemostasis, 2009, 102, 683-687.	1.8	32
46	History of nonâ€fatal cardiovascular disease in a cohort of <scp>D</scp> utch and <scp>B</scp> ritish patients with haemophilia. European Journal of Haematology, 2012, 89, 336-339.	1.1	32
47	Usefulness of a semiquantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients. American Journal of Medicine, 2002, 112, 617-621.	0.6	31
48	Challenges and controversies in haemophilia care in adulthood. Haemophilia, 2009, 15, 20-27.	1.0	31
49	Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. Thrombosis Research, 2014, 133, 390-395.	0.8	31
50	Up-regulation of platelet activation in hemophilia A. Haematologica, 2011, 96, 888-895.	1.7	30
51	Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine, 2021, 32, 100726.	3.2	30
52	Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. The Cochrane Library, 2015, , CD011385.	1.5	29
53	Toward Flow Cytometry Based Platelet Function Diagnostics. Seminars in Thrombosis and Hemostasis, 2018, 44, 197-205.	1.5	29
54	Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline. Haemophilia, 2013, 19, 370-377.	1.0	27

#	Article	IF	CITATIONS
55	A prognostic model for short term adverse events in normotensive patients with pulmonary embolism. American Journal of Hematology, 2011, 86, 646-649.	2.0	26
56	Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice. Thrombosis and Haemostasis, 2013, 110, 173-183.	1.8	26
57	Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. Haemophilia, 2015, 21, 419-429.	1.0	26
58	Facilitating the implementation of pharmacokineticâ€guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia, 2016, 22, e1-e10.	1.0	26
59	The association of haemophilic arthropathy with Healthâ€Related Quality of Life: a <i>post hoc</i> analysis. Haemophilia, 2016, 22, 833-840.	1.0	26
60	Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: a retrospective observational study. BMJ Open, 2017, 7, e012789.	0.8	26
61	Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. Blood Reviews, 2020, 39, 100633.	2.8	26
62	Partial pyruvate kinase deficiency aggravates the phenotypic expression of band 3 deficiency in a family with hereditary spherocytosis. American Journal of Hematology, 2015, 90, E35-9.	2.0	25
63	Rituximab-induced serum sickness. British Journal of Haematology, 2006, 135, 147-147.	1.2	24
64	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493.	1.7	24
65	Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. Haemophilia, 2013, 19, 744-752.	1.0	22
66	The "OPTI-CLOT―trial. Thrombosis and Haemostasis, 2015, 114, 639-644.	1.8	22
67	Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. Journal of Vascular Surgery, 2017, 65, 1519-1527.e26.	0.6	22
68	Antiâ€Î²2â€glycoprotein I and antiâ€prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. Journal of Thrombosis and Haemostasis, 2021, 19, 1018-1028.	1.9	22
69	Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood, 2021, 137, 2997-3001.	0.6	22
70	Management of atrial fibrillation in people with haemophilia – a consensus view by the <scp>ADVANCE</scp> Working Group. Haemophilia, 2014, 20, e417-20.	1.0	21
71	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia, 2018, 24, e33-e49.	1.0	21
72	Treatment of acquired hemophilia A, a balancing act: results from a 27â€year Dutch cohort study. American Journal of Hematology, 2021, 96, 51-59.	2.0	21

#	Article	IF	CITATIONS
73	Oxygen gradient ektacytometryâ€derived biomarkers are associated with vasoâ€occlusive crises and correlate with treatment response in sickle cell disease. American Journal of Hematology, 2021, 96, E29-E32.	2.0	21
74	Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, openâ€label study. American Journal of Hematology, 2022, 97, .	2.0	21
75	Longâ€ŧerm effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia, 2016, 22, 852-858.	1.0	19
76	A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damagein vitroandin vivo. Journal of Thrombosis and Haemostasis, 2017, 15, 1788-1798.	1.9	19
77	Movement behaviour in adults with haemophilia compared to healthy adults. Haemophilia, 2018, 24, 445-451.	1.0	19
78	Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. The Cochrane Library, 2018, 7, CD012293.	1.5	19
79	Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. Blood Advances, 2020, 4, 5025-5034.	2.5	19
80	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. Clinical Pharmacokinetics, 2021, 60, 1395-1406.	1.6	19
81	Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia, 2009, 15, 1215-1218.	1.0	18
82	Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ib and Fc Rlla in immune thrombocytopenia. Haematologica, 2013, 98, e70-e72.	1.7	18
83	Role of glycoprotein lbα mobility in platelet function. Thrombosis and Haemostasis, 2010, 103, 1033-1043.	1.8	17
84	The Early Course of D-dimer Concentration following Pulmonary Artery Embolisation. Thrombosis and Haemostasis, 2001, 86, 1578-1579.	1.8	16
85	No Influence of Heparin Plasma and Other (Pre)analytic Variables on D-Dimer Determinations. Clinical Chemistry, 2002, 48, 1611-1613.	1.5	16
86	Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency. Journal of Thrombosis and Haemostasis, 2020, 18, 706-713.	1.9	16
87	Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. Journal of Thrombosis and Haemostasis, 2014, 12, 237-245.	1.9	15
88	An update on the â€~danger theory' in inhibitor development in hemophilia A. Expert Review of Hematology, 2019, 12, 335-344.	1.0	15
89	Clinical preâ€ŧest probability adjusted versus ageâ€adjusted Dâ€dimer interpretation strategy for DVT diagnosis: A diagnostic individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 669-675.	1.9	15
90	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances, 2022, 6, 902-908.	2.5	15

#	Article	IF	CITATIONS
91	Stimulation of NaÃ⁻ve Monocytes and <scp>PBMC</scp> s with Coagulation Proteases Results in Thrombinâ€Mediated and <scp>PAR</scp> â€1â€Dependent Cytokine Release and Cell Proliferation in <scp>PBMC</scp> s Only. Scandinavian Journal of Immunology, 2013, 77, 339-349.	1.3	14
92	Anticoagulation therapy in haemophilia. Hamostaseologie, 2013, 33, 299-304.	0.9	14
93	Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. Journal of Thrombosis and Haemostasis, 2017, 15, 868-875.	1.9	14
94	Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. Translational Research, 2004, 144, 100-107.	2.4	13
95	Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice. Thrombosis and Haemostasis, 2014, 112, 1044-1050.	1.8	13
96	First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. British Journal of Haematology, 2015, 171, 424-427.	1.2	13
97	AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. Blood, 2020, 136, 26-26.	0.6	13
98	The role of fibrin monomers in optimizing the diagnostic work-up of deep vein thrombosis. Thrombosis and Haemostasis, 2007, 97, 807-813.	1.8	12
99	Reliability and Feasibility of the Self-Administered ISTH-Bleeding Assessment Tool. TH Open, 2019, 03, e350-e355.	0.7	12
100	Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients. Blood Reviews, 2021, 47, 100774.	2.8	12
101	Terminal halfâ€life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis, 2021, 19, 1896-1906.	1.9	12
102	Continuous infusion of recombinant factor <scp>VIII</scp> formulated with sucrose in surgery: Nonâ€interventional, observational study in patients with severe haemophilia A. Haemophilia, 2015, 21, e19-25.	1.0	11
103	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11
104	Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 212-214.	0.9	11
105	Movement behaviour patterns in adults with haemophilia. Therapeutic Advances in Hematology, 2020, 11, 204062071989695.	1.1	11
106	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial. PLoS Medicine, 2020, 17, e1003142.	3.9	11
107	Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. Blood Reviews, 2021, 49, 100826.	2.8	11
108	A Blended Physiotherapy Intervention for Persons With Hemophilic Arthropathy: Development Study. Journal of Medical Internet Research, 2020, 22, e16631.	2.1	11

#	Article	IF	CITATIONS
109	A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 12-18.	0.6	10
110	Clot lysis phenotype and response to recombinant factor <scp>VII</scp> a in plasma of haemophilia A inhibitor patients. British Journal of Haematology, 2013, 162, 827-835.	1.2	10
111	Management of cardiovascular disease in aging persons with haemophilia. Hamostaseologie, 2017, 37, 196-201.	0.9	10
112	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. Thrombosis and Haemostasis, 2018, 118, 1690-1700.	1.8	10
113	<p>The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study</p> . Patient Preference and Adherence, 2020, Volume 14, 163-171.	0.8	10
114	Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. The Cochrane Library, 2019, 2019, CD011385.	1.5	10
115	Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTSâ€1 3 activity. Haemophilia, 2014, 20, 92-98.	1.0	9
116	Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Journal of Thrombosis and Haemostasis, 2018, 16, 2196-2207.	1.9	9
117	The Paediatric Haemophilia Activities List (pedHAL) in routine assessment: changes over time, childâ€parent agreement and informative domains. Haemophilia, 2019, 25, 953-959.	1.0	9
118	Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. American Journal of Hematology, 2020, 95, 1142-1147.	2.0	9
119	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502.	2.2	9
120	Treatment of patients with rare bleeding disorders in the Netherlands: Realâ€ l ife data from the RBiN study. Journal of Thrombosis and Haemostasis, 2022, 20, 833-844.	1.9	9
121	The early course of D-dimer concentration following pulmonary artery embolisation. Thrombosis and Haemostasis, 2001, 86, 1578-9.	1.8	9
122	Coagulation aggravates bloodâ€induced joint damage in dogs. Arthritis and Rheumatism, 2012, 64, 3231-3239.	6.7	8
123	How do patients and professionals differentiate between intraâ€articular joint bleeds and acute flareâ€ups of arthropathy in patients with haemophilia?. Haemophilia, 2016, 22, 368-373.	1.0	8
124	Joint assessment in von Willebrand disease. Thrombosis and Haemostasis, 2017, 117, 1465-1470.	1.8	8
125	Continuous infusion of extended halfâ€life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Haemophilia, 2018, 24, e280-e283.	1.0	8
126	A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. Pilot and Feasibility Studies, 2020, 6, 189.	0.5	8

#	Article	IF	CITATIONS
127	Adherence to prophylaxis and its association with activation of selfâ€management and treatment satisfaction. Haemophilia, 2021, 27, 581-590.	1.0	8
128	Application of <scp>SHAP</scp> values for inferring the optimal functional form of covariates in pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1100-1110.	1.3	8
129	Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect. Thrombosis Research, 2010, 126, 481-485.	0.8	7
130	Silencing of proteaseâ€activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice. Haemophilia, 2016, 22, 152-159.	1.0	7
131	Should vitamin K be supplemented instead of antagonised in patients with idiopathic pulmonary fibrosis?. Expert Review of Respiratory Medicine, 2018, 12, 169-175.	1.0	7
132	Catheter Ablation for Atrial Fibrillation in Patients with Hemophilia or von Willebrand Disease. TH Open, 2019, 03, e335-e339.	0.7	7
133	The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects. American Journal of Hematology, 2020, 95, E26-E28.	2.0	7
134	Biochemical marker research in hemophilic arthropathy: A systematic review. Blood Reviews, 2021, 47, 100781.	2.8	7
135	Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thrombosis and Haemostasis, 2022, 122, 208-215.	1.8	7
136	Platelet count and indices as postpartum hemorrhage risk factors: a retrospective cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 2873-2883.	1.9	7
137	Patientâ€reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. Haemophilia, 2022, 28, 197-214.	1.0	7
138	Menstrual problems in chronic immune thrombocytopenia: AÂmonthly challenge ―a cohort study and review. British Journal of Haematology, 2022, 198, 753-764.	1.2	7
139	Glucose 6-phosphate dehydrogenase deficiency in an elite long-distance runner. Blood, 2009, 113, 2118-2119.	0.6	6
140	A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab. Thrombosis and Haemostasis, 2011, 106, 383-385.	1.8	6
141	Joint surgery in von Willebrand disease: a multicentre crossâ€sectional study. Haemophilia, 2016, 22, 256-262.	1.0	6
142	The prevalence and burden of hand and wrist bleeds in von Willebrand disease. Haemophilia, 2019, 25, e35-e38.	1.0	6
143	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305.	1.9	6
144	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2245-2252.	1.9	6

#	Article	IF	CITATIONS
145	Congenital platelet disorders and health status–related quality of life. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 100-105.	1.0	6
146	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613.	1.1	6
147	Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items. Haemophilia, 2021, 27, 1062-1070.	1.0	6
148	The role of fibrin monomers in optimizing the diagnostic work-up of deep vein thrombosis. Thrombosis and Haemostasis, 2007, 97, 807-13.	1.8	6
149	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	1.9	6
150	Who is at risk for occult cancer after venous thromboembolism?. Journal of Thrombosis and Haemostasis, 2006, 4, 2731-2733.	1.9	5
151	Screening for hemosiderosis in patients receiving multiple red blood cell transfusions. European Journal of Haematology, 2017, 98, 478-484.	1.1	5
152	Pathophysiological Mechanisms of Endogenous FVIII Release following Strenuous Exercise in Non-severe Haemophilia: A Review. Thrombosis and Haemostasis, 2017, 117, 2237-2242.	1.8	5
153	A Pathophysiological Perspective on the SARS oVâ€2 Coagulopathy. HemaSphere, 2020, 4, e457.	1.2	5
154	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1056-1065.	1.8	5
155	The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance. International Journal of Molecular Sciences, 2021, 22, 2204.	1.8	5
156	Coordinating physiotherapy care for persons with haemophilia. Haemophilia, 2021, 27, 1051-1061.	1.0	5
157	Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B. Blood, 2016, 128, 2314-2314.	0.6	5
158	Enhanced hepatic clearance of hyposialylated platelets explains thrombocytopenia in GNE-related macrothrombocytopenia. Blood Advances, 2022, 6, 3347-3351.	2.5	5
159	Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase <scp>III</scp> placeboâ€controlled randomized crossâ€over clinical trial. American Journal of Hematology, 2022, 97, 924-932.	2.0	5
160	Persistent Aâ€antigen after stem cell transplantation of blood group A patient with nonâ€A donor. American Journal of Hematology, 2012, 87, E118-9.	2.0	4
161	Successful transfusion care for a patient with the Rhesus -D- phenotype and antibodies against Rh17 and two additional alloantibodies. Annals of Hematology, 2012, 91, 963-964.	0.8	4
162	Platelet degranulation and glycoprotein IIbIIIa opening are not related to bleeding phenotype in severe haemophilia A patients. Thrombosis and Haemostasis, 2014, 111, 1022-1030.	1.8	4

#	Article	IF	CITATIONS
163	The combination of urinary <scp>CTX</scp> â€ <scp>II</scp> and serum <scp>CS</scp> â€846: Promising biochemical markers to predict radiographic progression of haemophilic arthropathy—An exploratory study. Haemophilia, 2018, 24, e278-e280.	1.0	4
164	Proteoglycan synthesis rate as a novel method to measure bloodâ€induced cartilage degeneration in nonâ€haemophilic and haemophilic rats. Haemophilia, 2020, 26, e88-e96.	1.0	4
165	Relapse of immune thrombocytopenia after COVIDâ€19 vaccination. European Journal of Haematology, 2022, 108, 84-85.	1.1	4
166	Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE). Blood, 2021, 138, 2047-2047.	0.6	4
167	Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a crossâ€sectional study. British Journal of Haematology, 2022, 196, 215-223.	1.2	4
168	Checklist Individual Strength to measure severe fatigue in immune thrombocytopenia. British Journal of Haematology, 2022, 197, .	1.2	4
169	Gene Therapy for Hemophilia A: How Long Will It Last?. HemaSphere, 2022, 6, e720.	1.2	4
170	No firm association between N-terminal pro-brain natriuretic peptide and percentage of pulmonary vascular obstruction in patients with acute pulmonary embolism. Thrombosis Research, 2011, 127, 547-550.	0.8	3
171	Familial macrothrombocytopenia due to a double mutation <i>in cis</i> in the alphaâ€actinin 1 gene (<i>ACTN1</i>), previously considered to be chronic immune thrombocytopenic purpura. Pediatric Blood and Cancer, 2018, 65, e27418.	0.8	3
172	Challenges in biomarker research in haemophilic arthropathy. Haemophilia, 2021, 27, e547-e548.	1.0	3
173	Onâ€demand treatment with the iron chelator deferasirox is ineffective in preventing bloodâ€induced joint damage in haemophilic mice. Haemophilia, 2021, 27, 648-656.	1.0	3
174	A simplified decision rule to rule out deep vein thrombosis using clinical assessment and Dâ€dimer. Journal of Thrombosis and Haemostasis, 2021, 19, 1752-1758.	1.9	3
175	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2021, 47, 724-734.	1.5	3
176	Tranexamic Acid Is Not a Universal Hemostatic Agent. HemaSphere, 2021, 5, e625.	1.2	3
177	Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy. Blood, 2018, 132, 3476-3476.	0.6	3
178	Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIIIâ€ŧreated patients with haemophilia A switching to turoctocog alfa in a noninterventional study. Haemophilia, 2022, 28, 46-54.	1.0	3
179	Repeated NT-proBNP testing and risk for adverse outcome after acute pulmonary embolism. Thrombosis and Haemostasis, 2011, 106, 1226-1227.	1.8	2
180	Does haemophilia protect against ischaemic cardiovascular disease?. Haemophilia, 2012, 18, e35-6.	1.0	2

#	Article	IF	CITATIONS
181	Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism. Blood Coagulation and Fibrinolysis, 2013, 24, 297-304.	0.5	2
182	Cataract surgery in haemophilia. Haemophilia, 2013, 19, e371-e372.	1.0	2
183	First preclinical support for the †danger theory' in inhibitor development. Haemophilia, 2016, 22, 654-656.	1.0	2
184	Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing oral or dental procedures. The Cochrane Library, 2016, , .	1.5	2
185	Hemophilic Arthropathy. , 2017, , 2007-2017.		2
186	Organ involvement occurs in all forms of hereditary haemolytic anaemia. British Journal of Haematology, 2019, 185, 602-605.	1.2	2
187	Obstetrical bleeding in women with MYH9â€related disease—A systematic review. Haemophilia, 2021, 27, e278-e283.	1.0	2
188	Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A. HemaSphere, 2021, 5, e557.	1.2	2
189	Glanzmann thrombasthenia complicated by frequent myeloproliferative neoplasmâ€related thromboembolism: thrombosis occurring regardless of αIIbβIII integrin deficiency. Clinical Case Reports (discontinued), 2021, 9, e04757.	0.2	2
190	Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc. TH Open, 2020, 04, e362-e364.	0.7	2
191	Identification of Biomarkers That Are Associated with Clinical Complications of Hemoglobin SC Disease and Sickle Cell Anemia. Blood, 2021, 138, 962-962.	0.6	2
192	Cyproterone acetate- and ethinyloestradiol-containing oral contraceptive as a risk factor for upper extremity deep venous thrombosis–a case report. European Journal of Contraception and Reproductive Health Care, 2009, 14, 160-163.	0.6	1
193	Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay. Blood Coagulation and Fibrinolysis, 2011, 22, 506-511.	0.5	1
194	Core diameter of bone marrow aspiration devices influences cell density of bone marrow aspirate in patients with severe peripheral artery disease. Cytotherapy, 2015, 17, 1807-1812.	0.3	1
195	Stay Tuned on Statins: The New Panacea?. HemaSphere, 2018, 2, e47.	1.2	1
196	Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline. TH Open, 2021, 05, e489-e502.	0.7	1
197	The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia. Blood, 2018, 132, 2360-2360.	0.6	1
198	No Association Between Platelet Function and Hemophilia B Phenotype. Blood, 2014, 124, 4994-4994.	0.6	1

#	Article	IF	CITATIONS
199	Renal Status and Hematuria in Older Patients with Hemophilia. Blood, 2015, 126, 2290-2290.	0.6	1
200	Interleukin-1β Is Essential for Blood-Induced Cartilage Damage In Vitro. Blood, 2014, 124, 240-240.	0.6	1
201	Clinical Joint Outcome after Joint Bleeds in Patients with Von Willebrand Disease Is Comparable to Moderate and Severe Hemophilia A Despite Fewer Joint Bleeds. Blood, 2016, 128, 3789-3789.	0.6	1
202	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open, 2022, 06, e60-e69.	0.7	1
203	No influence of heparin plasma and other (pre)analytic variables on D-dimer determinations. Clinical Chemistry, 2002, 48, 1611-3.	1.5	1
204	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere, 2022, 6, e694.	1.2	1
205	Diagnostic performance of D-dimer is lower in elderly outpatients with suspected deep venous thrombosis: response to Aguilar & del Villar. British Journal of Haematology, 2005, 130, 805-805.	1.2	Ο
206	Acquired thrombotic thrombocytopenic purpura (TTP): Is plasmapheresis enough?. Transfusion and Apheresis Science, 2009, 40, 129.	0.5	0
207	Scuba diving by patients with haemophilia: a few notes of precaution. Haemophilia, 2011, 17, e1007-e1008.	1.0	0
208	Comment on â€~Stem-cell Therapy for Peripheral Arterial Occlusive Disease'. European Journal of Vascular and Endovascular Surgery, 2012, 43, 486.	0.8	0
209	Response to desmopressin in patients with mild hemophiliaÂA caused by the F8 c.1910A>G, p.Asn637Ser mutation. Journal of Thrombosis and Haemostasis, 2013, 11, 2179-2181.	1.9	0
210	A patient with severe haemophilia A and multiple arterial thromboses caused by large vessel vasculitis: a case report. Haemophilia, 2016, 22, e39-e42.	1.0	0
211	Gene Therapy in Hemophilia: From Hype to Hope. HemaSphere, 2018, 2, e37.	1.2	0
212	No Relation between Platelet Activity and Haemophilia B Phenotype. Thrombosis and Haemostasis, 2018, 118, 1481-1483.	1.8	0
213	The Long and Winding Road for New Treatments for Acquired Thrombotic Thrombocytopenic Purpura. HemaSphere, 2019, 3, e177.	1.2	0
214	Prevalence and Characteristics of Occult Cancer in Patients with Venous Thromboembolism Blood, 2005, 106, 1623-1623.	0.6	0
215	Role of Glycoprotein Ibα Mobility in Platelet Function Blood, 2008, 112, 1850-1850.	0.6	0
216	Improving the Efficacy of Non-Radiologic Exclusion of Deep Venous Thrombosis in the Elderly Using the Thrombin Generation Assay. Blood, 2008, 112, 3815-3815.	0.6	0

#	Article	IF	CITATIONS
217	Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-ProBNP Level Blood, 2009, 114, 3996-3996.	0.6	0
218	Multiple joint procedures in haemophilia: benefit of self-reported activities. The Journal of Haemophilia Practice, 2016, 3, 55-61.	0.2	0
219	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, 2016, 128, 207-207.	0.6	0
220	Phosphatidylserine-Exposing Extracellular Vesicles after Splenectomy Are Associated with Increased D-Dimers and Fibrin Generation in Hereditary Hemolytic Anemia. Blood, 2018, 132, 630-630.	0.6	0
221	FXII: The Cuckoo in the Nest. HemaSphere, 2018, 2, e154.	1.2	0
222	Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study. Blood, 2021, 138, 2109-2109.	0.6	0
223	Title is missing!. , 2020, 17, e1003142.		0
224	Title is missing!. , 2020, 17, e1003142.		0
225	Title is missing!. , 2020, 17, e1003142.		0
226	Title is missing!. , 2020, 17, e1003142.		0